Metformin therapy in girls with polycystic ovary syndrome: A self-controlled clinical trial

Archives of Iranian Medicine

Volumn 10, Issue 2, 2007, Pages 176-181

  Nazari, Tahereh ^a   Bayat, Roya ^a   Hamedi, Mahdis ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hirsutism; Metformin; Obesity; Polycystic ovary syndrome

Indexed keywords

APOMETFORMIN; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; HYDROXYPROGESTERONE; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HIRSUTISM; HUMAN; IRAN; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; PROGESTERONE BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; DEHYDROEPIANDROSTERONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; LUTEINIZING HORMONE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TREATMENT OUTCOME;

EID: 34247630590     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab. 2002; 87: 569-574.
2. Hahn S, Quadbeck B, Elsenbruch S, Gartner R, Finke R, Mann K, et al. Metformin, an efficacious drug in the treatment of polycystic ovary syndrome [in German]. Dtsch Med Wochenschr. 2004; 129: 1059-1064.
3. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001; 28: 99-109.
4. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003; 327: 951-953.
5. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 1988; 50: 197-212.
6. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992; 71: 599-604.
7. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999; 28: 361-378.
8. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women, J Clin Endocrinol Metab. 1999; 84: 165-169.
9. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997; 90: 392-395.
10. Wollen N, Bailey CJ. Metformin potentiates the antigluconeogenic action of insulin. Diabete Metab. 1988; 14: 88-91.
11. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998; 338: 1876- 1880.
12. Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome - beyond ovulation induction. Hum Reprod. 2002; 17: 3016-3026.
13. Vrbikova J, Hill M, Starka L, Vondra K. Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecol Obstet Invest. 2002; 53: 100-104.
14. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation, J Clin Endocrinol Metab. 2000; 85: 139-146.
15. Homburg R. Polycystic Ovary Syndrome. London: Martin Dunitz; Malden, MA: Distributed in the U.S. by Blackwell Science; 2001.
16. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996; 335: 617-623.
17. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994; 43: 647-654.
18. Casmiri F, Bisscotti M, Gambineri S. Metformin improves insulin, body fat distribution, and androgen in obese owmen with and without the polycystic ovary syndrome. Int Obstity. 1997; 3: 561.
19. Morin-Papunen L, Koviunen R, Ruokenon A. Metformin therapy improves menstrual pattern of endocrine and metabolic effect in women with polycystic ovary syndrome. Fertil Steril. 1998; 69: 691-696.
20. Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 1996; 65: 946-949.
21. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary. syndrome, J Clin Endocrinol Metab. 1997; 82: 524-530.
22. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998; 138: 269-274.
23. Crave JC, Fimbel S, Lejelane H. Effect of diet and metformin administration on sex hormone binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab. 1995; 80: 2057-2062.
24. Kelly CS, Gordon S. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002; 147: 217-221.
25. Kazerooni T, Dehghan-Kooshkyhazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003; 17: 51-96.
26. Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol. 2003; 101: 785-793.
27. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994; 73: 460-468.
28. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome. Araudomized study. J Clin Endocrinol Metab. 2003; 88: 148-156.
29. Kumari AS, Haq A, Jayasundaram R. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed. 2005; 10: 100-104.
30. Chou KH, yon Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind, and placebo-controlled trial. Horm Metab Res. 2003; 35: 86-91.